Biomedical Engineering Reference
In-Depth Information
[184] Taljanski W , Pierzynowki SG , Lundin PD , Westrom BR , Eirefelt S , Podlesny J , et al .
Pulmonary delivery of intratracheally instilled and aerosolized cyclosporin A to young
and adult rats . Drug Metab Dispos 1997 ; 25 : 917 - 20 .
[185] Jaffe HA , Buhl R , Mastrangeli A , Holroyd KJ , Saltini C , Czerski D , et al . Organ-spe-
cific cytokine therapy: local activation of mononuclear phagocytes by delivery of an
aerosol of recombinant interferon-γ to the human lung . J Clin Invest 1991 ; 88 : 297 - 302 .
[186] Halme M , Maasilta P , Mattson K ,
Cantell K . Pharmacokinetics and toxicity of inhaled
human natural interferon-beta in patients with lung cancer . Respiration 1994 ; 61 : 105 - 7 .
[187] Halme M , Maasilta P , Repo H , Ristola M , Taskinen E , Mattson KV , et al . Inhaled
recombinant interferon gamma in patients with lung cancer: pharmacokinetics and
effects on chemiluminescence responses of alveolar macrophages and peripheral blood
neutrophils and monocytes . Int J Radiat Oncol Biol Phys 1995 ; 31 : 93 - 101 .
[188] A randomized, double-blinded, placebo-controlled, phase ii inhaled interferon gamma-
1b and antimycobacterials to treat pulmonary mycobacterium avium complex infections.
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). http://clinical-
trials.gov/ct2/show/NCT00021567. Accessed 6 December 2009.
[189] A pilot study of aerosol interferon-gamma for treatment of idiopathic pulmonary fibro-
sis. Sponsor: New York University School of Medicine. http://clinicaltrials.gov/ct2/
show/NCT00563212. Accessed on 6 December 2009.
[190] Green JD . Pharmaco-toxicological expert report. Pulmozyme rhDNase Genentech, Inc .
Hum Exp Toxicol 1993 ; 13 : S1 - 42 .
[191] Beasly R , Rafferty P , Holgate
ST . Adverse reactions to the non-drug constituents of
nebuliser solutions . Br J Clin Pharmacol 1988 ; 25 : 283 - 7 .
[192] Fois RA , Gonda I , Chan H . Tonicity of some commonly used drug preparations for neb-
ulisations . Aust J Hosp Pharm 1986 ; 16 : 19 - 21 .
[193] Aitken ML , Burke W , McDonald G , Shak S , Montgomery AB , Smith
A . Recombinant
human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase 1
study . JAMA 1992 ; 267 : 1947 - 51 .
[194] Hubbard RC , McElvaney NG , Birrer P , Shak S , Robinson WW , Jolley C , et al . A pre-
liminary study of aerosolized recombinant human deoxyribonuclease I in the treatment
of cystic fibrosis . N Engl J Med 1992 ; 326 : 812 - 15 .
[195] Wagener JS , Rock MJ , Mccubbin MM , Hamilton SD , Johnson CA , Abrens RC . Aerosol
delivery and safety of recombinant human deoxyribonuclease in young children with
cystic fibrosis: a bronchoscopic study . J Pediatr 1998 ; 133 : 486 - 91 .
[196] Barrowcliffe MP , Morice A , Jones JG , Sever PS . Pulmonary clearance of vasoactive
intestinal peptide . Thorax 1986 ; 41 : 88 - 93 .
[197] Ohmori Y , Onoue S , Endo K , Matsumoto A , Uchida A , Yamada S . Development of dry
powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pul-
monary administration . Life Sci 2006 ; 79 : 138 - 43 .
[198] Leuchte HH , Baezner C , Baumgartner
RA , Bevec D , Bacher G , Neurohr C , et al .
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
. Eur Respir J
2008 ; 32 : 1289 - 94 .
[199] Moses AC , Gordon GS , Carey MC , Flier JS . Insulin administered intranasally as an
insulin-bile salt aerosol . Diabetes 1983 ; 32 : 1040 - 7 .
[200] Illum L , Jorgensen H , Bisgaard H , Krogsgaard O , Rossing N . Bioadhesive microspheres
as a potential nasal drug delivery system . Int J Pharm 1987 ; 39 : 189 - 99 .
[201] Colthrope P , Farr SJ , Taylor G ,
Taylor G , Smith IJ , Wyatt D . The pharmacokinetics of
pulmonary delivered insulin: a comparison of intratracheal and aerosol administration
to the rabbit . Pharm Res 1992 ; 6 : 9764 - 8 .
Search WWH ::




Custom Search